（原标题：阿尔及利亚制药工业覆盖全国80%的药品需求） 《曙光报》12月16日报道，阿尔及利亚医药工业部药品生产促进司副司长杜尼娅·布德尔巴尔表示，目 前阿尔及利亚通过分布在多个省份的200多家制药生产单位，已能够满足全国约80%的药品需求，其中 包括10家专门生产抗癌药物的工厂，这反映了该行业的显著发展以及国家层面的战略布局。 布德尔巴尔还表示，阿尔及利亚不仅能够满足非洲市场需求，也具备向非洲以外地区供货的能力。目 前，阿已向阿曼、沙特等中东国家出口药品，尤其是胰岛素。她强调，国家制药产能已完全能够覆盖国 内市场，并支持进一步开拓国际市场。 此外，她强调阿方正持续加大在医疗耗材领域的投资吸引力度，通过推进程序数字化、简化审批流程以 及制定精准的产业布局规划，提升本地生产能力、降低进口成本。 她还提到，2025年11月27日至29日，于阿尔及利亚举办的非洲药品生产部长级会议取得了积极成果，本 次会议汇聚了29个非洲国家、700多名与会代表，以及包括联合国儿童基金会、联合国工业发展组织和 非洲疾病预防控制中心在内的多家国际机构，充分体现了保障非洲大陆药品可及性的战略重要性。会议 期间，与会各方就卫生领域自给自足 ...

Core Insights - The Chinese pharmaceutical industry is accelerating towards high-quality development, with continuous improvements in innovative drug research and industrialization levels [1][2] - The China International Import Expo (CIIE) has evolved into a comprehensive platform for showcasing, communication, and cooperation, significantly benefiting global pharmaceutical companies entering the Chinese market [1][2] - Novartis is showcasing nearly 20 innovative products across four core therapeutic areas at this year's CIIE, emphasizing its commitment to innovation and accessibility in the Chinese market [1][3] Industry Development - In recent years, China's pharmaceutical industry has seen rapid growth, with significant enhancements in innovation capabilities and international influence [2] - The Chinese pharmaceutical market is projected to grow from $252.37 billion in 2024 to $274.66 billion in 2025, reaching $540.78 billion by 2032, with a compound annual growth rate (CAGR) of 10.16% [2] Novartis' Strategic Focus - Novartis is focusing on five key technology platforms, including radioligand therapy (RLT), to showcase its global research and development capabilities at the CIIE [3][4] - The company plans to synchronize over 90% of new drug registrations and indications in China with global timelines within the next two years [3] Investment and Infrastructure - Novartis announced a $6 billion investment to establish a radiopharmaceutical production base in Haiyan, Zhejiang, which is expected to be operational by the end of 2026 [4][5] - The investment reflects Novartis' long-term commitment to the Chinese market and the role of CIIE in facilitating the transformation of innovative results into practical value [5] Accessibility and Patient Care - Novartis has been recognized for its commitment to drug accessibility, ranking first in the global drug accessibility index in 2024 [6] - The company has participated in national medical insurance negotiations, with nearly 40 innovative drugs included in the national medical insurance directory since 2017 [6] Community Engagement and Education - Novartis is actively involved in enhancing grassroots medical services and has supported various projects to improve healthcare delivery in rural areas [7][8] - The company has developed a multi-layered accessibility system, benefiting approximately 80.7 million Chinese patients from its innovative drugs in 2024 [8] Future Outlook - China's pharmaceutical innovation pipeline is robust, with 3,575 active innovative drugs developed by Chinese companies from 2015 to 2024, surpassing the United States [9] - The "spillover effect" of the CIIE is expected to continue amplifying, positioning China as a crucial node for global research and results implementation [9]